(Q42909155)

10 November 2017

Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics (English)

1 reference

10 November 2017

Masaru Katoh

1

1 reference

PubMed ID

20836672

10 November 2017

language of work or name

1 reference

1 September 2010

1 reference

Expert Review of Anticancer Therapy

10 November 2017

1 reference

10 November 2017

10

1 reference

10 November 2017

1375-1379

1 reference

10 November 2017

9

1 reference

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

10 November 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Cellular signaling by fibroblast growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Mechanisms underlying differential responses to FGF signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

FGFRI andPLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Modeling genomic diversity and tumor dependency in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Genome-wide association study identifies novel breast cancer susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

WNT signaling pathway and stem cell signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

Functional FGFR4 Gly388Arg Polymorphism Predicts Prognosis in Lung Adenocarcinoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.128

21 January 2018

Identifiers

DOI

10.1586/ERA.10.128

1 reference

10 November 2017

1 reference

PubMed ID

20836672